Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 Enzymes

Biopharmaceutics and Drug Disposition

Volumn 21, Issue 9, 2000, Pages 353-364

  Cohen, L H ^a   Van Leeuwen, R E W ^b   Van Thiel, G C F ^a   Van Pelt, J F ^a   Yap, S H ^a  

^a TNO   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Atorvastatin; Cerivastatin; Cholesterol synthesis; Cytochrome P450; Fluvastatin; Human hepatocytes; Lovastatin; Pravastatin; Simian hepatocytes; Simvastatin

Indexed keywords

ANILINE; ATORVASTATIN; BUFURALOL; CERIVASTATIN; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ETHOXYRESORUFIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEPHENYTOIN; MEVINOLIN; NIFEDIPINE; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE;

ANIMAL CELL; AROMATIZATION; ARTICLE; ASSAY; CELL CULTURE; CELL SUSPENSION; CHOLESTEROL SYNTHESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEALKYLATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IC 50; INCUBATION TIME; LIVER; LIVER CELL; LIVER MICROSOME; MONKEY; NONHUMAN; TARGET ORGAN;

ANIMALS; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACACA FASCICULARIS;

EID: 0034428256     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.249     Document Type: Article

References (43)

1. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
2. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
3. 3-Hydroxy-3-methylgluratyl-coenzyme a reductase inhibitors. 4 side chain ester derivatives of mevinolin
4. Hypolipoproteinemic activity of XU 62-320, a potent competitive inhibitor of HMG-CoA reductase
5. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981-comparison with selected HMG-CoA reductase inhibitors
6. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
7. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
8. Pravastatin sodium: New clinical aspects and recent progress
9. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
10. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors on sterol synthesis in various human cell types
11. Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro
12. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle
13. Effect of synthetic HMG-CoA reductase inhibitors on cholesterol synthesis in various human cell types and on progesterone secretion from human granulosa cells in culture
14. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
15. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
16. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
17. Enzymes of sterol biosynthesis in liver and intermediates of sterol biosynthesis
18. Retinoids stimulate ApoA-I synthesis by induction of gene transcription in primary hepatocyte cultures from cynomolgus monkey (Macaca fascicularis)
19. The maintenance of cytochrome P-450 in rat hepatocyte culture
20. Influence of 48 hours of cold storage in University of Wisconsin organ preservation solution on metabolic capacity of rat hepatocytes
21. Cryopreservation of adult human hepatocytes. The influence of deep freezing storage on the viability, cell seeding, survival, fine structures and albumin synthesis in primary cultures
22. Ethoxyresorufin: Direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene
23. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol, and testosterone oxidation
24. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography
25. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver
26. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
27. Effect of cold and warm ischaemia on drug metabolism in isolated hepatocytes and slices from human and monkey liver
28. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s
29. Metabolism of cerivastatin by human liver microsomes in vitro-characterization of primary metabolic pathways and of cytochrome P450 isozymes involved
30. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
31. The interaction of diltiazem with lovastatin and pravastatin
32. Effect of itraconazole on the pharmacokinetics of atorvastatin
33. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
34. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
35. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
36. Rhabdomyolysis due to interaction of simvastatin with mibefradil
37. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
38. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
39. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
40. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
41. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
42. 'Fire and forget?'-pharmacological considerations in coronary care
43. Drug interactions with the cytochrome P 450 system